ArticleAnalytical chemistry2026
Iron Oxide-Based Surface-Enhanced Raman Spectroscopy Bioprobes for Detecting Tumor Cells in Serous Effusion.
Article in Analytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serous effusions, including pleural effusion and ascites, commonly occur in advanced cancers like lung and ovarian carcinomas. Detecting tumor cells in these effusions is crucial for assessing cancer metastasis. However, clinical methods mainly include cytological examination, which has limited sensitivity, and complex cell block technology that requires large volumes of serous effusion. Surface-enhanced Raman spectroscopy (SERS), with its high sensitivity and noninvasive nature, has emerged as a crucial tool for liquid biopsies. Building on this technology, a novel SERS bioprobe was specifically designed for the precise identification and capture of tumor cells in serous effusions, utilizing a composite material. The SERS bioprobes offer strong SERS enhancement, excellent spectral reproducibility, and molecular targeting, thereby enhancing detection specificity. Furthermore, SERS classification models were established to categorize samples based on tumor cell concentrations in serous effusions, enabling semiquantitative diagnostic capability. Notably, machine learning-assisted analysis enables rapid processing and classification of numerous Raman spectra and thorough feature extraction and greatly improves the SERS bioprobe's diagnostic accuracy. Consequently, the combination of SERS bioprobes and machine learning provides a rapid and effective detection method that overcomes the low sensitivity of conventional cytological detection in serous effusions and enables assessment of tumor cell concentration ranges within these fluids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.